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Incomplete Retention After Direct Myocardial Injection
P. Michael Grossman,1 MD, Zhenguo Han,1 MD, Maria Palasis,2 PhD, James J. Barry,2 PhD, and
Robert J. Lederman,1* MD
Direct intramyocardial injection may permit local delivery of protein and gene therapy
agents for myocardial and coronary artery disease. Little is known about the immediate
fate of materials administered via percutaneous endomyocardial catheters or via surgical
epicardial injection. In this study, we use a novel method to evaluate the acute retention
of agents injected directly into the myocardium, compare epicardial with the percutane-
ous endocardial and postmortem delivery, and evaluate the influence of injectate volume
on myocardial retention. Fifteen 40–50 kg pigs underwent overlapping myocardial injec-
tions using a percutaneous endomyocardial catheter, an epicardial needle via an open
chest, and epicardial needle postmortem. Multiple distinct 15  neutron-activated mi-
crosphere species were used as tracers. Two or three myocardial walls were injected in
each animal using 3.5 mm, 27–28 gauge needles at varying injectate volumes. Animals
were sacrificed immediately. Myocardial walls were divided and multiple microsphere
species were quantified. In an additional study, nine 70 kg pigs underwent percutaneous
endomyocardial injections with replication-deficient adenovirus encoding for the pro-
duction of lac-Z. The injectate volume was varied, while the viral particle number re-
mained constant. The animals were sacrificed 5 days after the percutaneous injections;
the heart, liver, and spleen were collected for -galactosidase activity. Endomyocardial
injection was associated with 43%  15% microsphere retention, compared with 15% 
21% (P < 0.01) retention of open chest epicardial injection and 89%  60% (P < 0.01) for
postmortem injection. Reducing the injectate volume from 100 to 10 L improved micro-
sphere retention (P  0.01). There was a trend toward improved viral transfection asso-
ciated with smaller injection volumes. Despite direct intramyocardial administration, a
significant fraction of injectate is not retained locally. Catheter-based needle endomyo-
cardial injection is associated with equivalent or superior injectate retention compared
with open chest epicardial injection. Proportionately, more injectate may be retained at
lower volumes. Loss may involve a combination of channel leakage, venous, and lym-
phatic return. Cathet Cardiovasc Intervent 2002;55:392–397. © 2002 Wiley-Liss, Inc.
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INTRODUCTION
A variety of emerging molecular interventions may
prove useful in the treatment of coronary artery and
myocardial disease. Methods for delivery of therapeutic
agents to the cardiac tissues include intravenous [1],
intra-arterial [2], intracoronary [3], pericardial [4,5], and
direct myocardial routes using an epicardial surgical [6]
or catheter-based endocardial approach [7–9].
Direct myocardial injection is attractive because spe-
cific myocardial regions can be targeted and high local
tissue concentrations, theoretically, can be achieved. In
addition, local drug delivery might permit an overall
dosage reduction, with attendant reduction in systemic
toxicity [10,11]. However, little is known about the abil-
ity of myocardium to retain injected material after per-
cutaneous endomyocardial catheter or direct epicardial
injection.
In these large-animal experiments, we evaluate the
acute retention of agents injected directly into the myo-
cardium, both epicardially and via a new percutaneous
endomyocardial catheter. In addition, we consider the
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The University of Michigan Committee on the Use
and Care of Animals approved all protocols. Healthy
farm swine (40–70 kg) were sedated with xylazine (2.2
mg/kg) intramuscularly (i.m.), telazol (6.0 kg/mg) i.m.,
and atropine (0.04 mg/kg) i.v. and received continuous
isoflurane (2%–2.5%) inhalation and mechanical venti-
lation.
Endomyocardial injections were performed with the
Stiletto 28G Endomyocardial Injection System (Boston
Scientific, Natick, MA). A transfemoral 9 Fr sheath was
advanced into the left ventricle under fluoroscopic guid-
ance and a coaxial 7 Fr steering guide directed the
Stiletto needle injection catheter to the desired LV terri-
tory. The Stilletto was advanced to the endomyocardial
surface using monoplane fluoroscopic guidance, and
catheter tip stability was confirmed manually and fluo-
roscopically. A spring-loaded needle penetrates 3.5 mm
into the endomyocardial wall. Injectate was introduced
into the LV using a 1 mL or Hamilton 100 L syringe
(Hamilton, Reno, NV). Injectate was administered over a
15-sec interval. The needle was retracted and then the
catheter was withdrawn and redirected to other sites.
Epicardial injections were performed systematically
after all endocardial injections, at which point the ster-
num and pericardium were opened. Epicardial injections
were performed using 27G butterfly needles, each angled
90°, yielding a 3.5 mm distal tip to give reproducible
needle depth on a beating heart. For all injections, one
operator controlled the needle and another performed
injections.
Microsphere Retention Experiments
Neutron-activated microspheres (Biophysics Assay
Laboratory, Wellesley Hills, MA) having a mean 15 
diameter were used as tracers. A distinct heavy-metal
tracer, gold, samarium, or iridium, was used for each
method of injection. The microsphere concentration was
2.5  106/mL. The microsphere stock solution (3 mL)
was mixed with 0.1 mL of ethylene blue dye (1%),
bromcresol green dye (1%), or bromcresol purple dye
(1%).
Three groups of five 40–50 kg pigs each underwent
10, 20, and 100 L injections. Individual animals under-
went three overlapping myocardial injections to the same
myocardial segment using a fluoroscopically guided per-
cutaneous endomyocardial catheter, open chest epicar-
dial needle, and a postmortem epicardial control injec-
tion. Each needle remained in the myocardium for a total
of 15 sec. After all injections were completed, the ani-
mals were sacrificed immediately with intravenous so-
dium pentobarbital (17 mg/kg), and the heart was col-
lected. Injection sites were localized by gross
examination of the endocardial surface. The myocardial
walls were divided into three sections, anterior, inferior,
and lateral, with localized dye tracer staining in the
center of the sections. An overlapping injection of an
equivalent volume of a distinct microsphere tracer was
injected into the postmortem myocardial sections. In
addition, myocardial sections remote to the microsphere
injection sites (septum and right ventricle) were col-
lected. The individual myocardial walls were sectioned
and placed in tracer-free polypropylene vials. Control
samples of the injectate were also placed directly into
tracer-free vials and air-dried. All samples were shipped
to a core laboratory (Biophysics Assay Laboratory) for
neutron activation and analysis [12,13]. This permits
quantification of multiple microsphere species in a single
specimen.
Adenoviral Lac-Z Delivery Experiments
Nine 70 kg pigs underwent endomyocardial injection
using the percutaneous myocardial injection catheter. A
replication-defective adenovirus containing a lac-Z gene
construct was used as a tracer. A constant number of viral
particles (1010) were administered during each injection,
although injectate volume was varied. The injectate vol-
ume was 10 L in three animals, 20 L in three animals,
and 100 L in three animals. Under fluoroscopic guid-
ance, the Stiletto Endomyocardial Injection System was
used to deliver an array of 10 discrete injections, spaced
1 cm apart, to the anterior wall of each animal. After-
ward, the catheter and sheath were removed, the femoral
artery cut-down site was repaired, the animal was recov-
ered and then sacrificed 5 days afterward. Tissue samples
were collected and snap-frozen in liquid nitrogen. -ga-
lactosidase expression was batch-assayed in homoge-
nized samples of anterior LV wall, inferior LV wall, right
ventricle, coronary sinus, liver, and spleen.
All samples were stored at 70°C until weighed and
pulverized under liquid nitrogen using a SPEX 6800
freezer mill (SPEX CertiPrep, Metuchen, NJ). Frozen,
pulverized tissue (50 mg) was solubilized in 500 mL of
lysis buffer (250 mM Tris HCl, 0.5% Triton X-100, 50
mg/mL leupeptin, 100 mg/mL aprotinin, and 200 mg/mL
Pefabloc, pH 7.4), centrifuged for 10 min at 14,000 rpm,
and the supernatant was analyzed using the Stratagene
High Sensitivity -Galactosidase Staining Kit (catalog
no. 200710; Stratagene, La Jolla, CA). The optical den-
sity was measured at 570–595 nm. The relative units of
-galactosidase per mg of tissue protein were multiplied
by the myocardial tissue weight. Data were expressed as
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total units of -galactosidase (U) for myocardial tissue,
or units -galactosidase per mg tissue protein (U/mg) for
coronary sinus, right ventricle, liver, and spleen.
Statistics
Continuous parameters were tested using analysis of
variance and a two-tailed student’s t-test using Bonfer-
roni or Dunnet corrections for multiple comparisons as




The endocardial and the epicardial injections were
well tolerated in all animals. Injections induced isolated
ventricular ectopic beats but no sustained dysrhythmia.
Postmortem examination revealed no evidence of myo-
cardial perforation or disruption of the mitral valve ap-
paratus. Dye staining corresponding to endocardial and
epicardial injections was identified in predicted myocar-
dial segments.
Microsphere Retention
Less material was retained after endomyocardial injec-
tions or after epicardial injections compared with post-
mortem injections. When data from all injection volumes
was pooled and compared with control specimens that
were injected directly into a sample vial, microsphere
retention was 43%  15% (P  0.01 compared with
postmortem controls) after endomyocardial, 15%  21%
after epicardial (P  0.01 compared with postmortem
controls), and 89%  60% after postmortem injections.
In addition, there was greater retention of injectate by the
catheter-based endocardial compared with the epicardial
injection approach (P  0.01; Fig. 1).
Injection Volume and Microsphere Retention
Proportionately more microspheres were retained after
smaller-volume, 10 or 20 l injections than after 100 l
injections (P  0.01 and 0.02, respectively). Compared
with control samples, the percentage of microspheres
retained in the myocardium after 10, 20, and 100 l
endomyocardial injections was 98%  85, 40%  48%,
and 20%  25%, respectively. The percentage of micro-
spheres retained after 10, 20, and 100 l epicardial
injections was 36%  50%, 19%  17%, and 9%  9%,
respectively. There was a trend toward superior retention
after endocardial injections compared with epicardial
injections. This difference approached statistical signifi-
cance at each individual volume (P  0.06 for 10 l
injections, P  0.07 for 20 l injections, and P  0.10
for 100 l injections). With all volumes pooled, there
was a significant difference between retention of inject-
ate after endocardial compared with epicardial injections,
with a P  0.01 after Dunnet correction for multiple
comparisons (Fig. 2).
Viral Transfection After Endomyocardial Injection
An equivalent number of adenoviral particles encod-
ing for the production of Lac-Z was injected. After
correction for multiple comparisons, there was a trend
toward improved viral transfection associated with the
smaller injection volumes, 10 and 20 l, compared with
the 100 l injection volume (P  0.08 and 0.19, respec-
tively; Fig. 3).
Fig. 1. The site of injection influences microsphere retention.
Compared with postmortem control injections, there was sig-
nificantly less material retained after endomyocardial injection
(p < 0.01) or epicardial injection (p < 0.01). In addition, there
was greater retention of microspheres associated with endo-
myocardial injection compared with epicardial injection (p <
0.01). Statistics are corrected for multiple comparisons as de-
scribed in methods.
Fig. 2. The injection volume influences microsphere retention.
Proportionally more microspheres were retained after smaller-
volume injections than after larger volume injections. These
differences were statistically significant for both endocardial
and epicardial injection methods. In addition, there was supe-
rior retention of injectate after endocardial injections compared
with epicardial injections. This approached statistical signifi-
cance at each individual injection volume.
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Coronary Sinus Tissue
There was marginally more -galactosidase activity in
the coronary sinus tissue from the animals receiving 100
l injections compared with those animals receiving
lower volume injections, (Fig. 4). This may indicate that
a greater proportion of the larger volume injections are
lost to the coronary venous system.
Viral Transfection in Nontarget Organs
There was evidence of significant viral transfection in
the liver and spleen (Table I).
Direct Leakage
Leakage of injected material from the injection site
was observed during and immediately after all epicardial
injections. The volume of this leaked material could not
readily be quantified. During continuous intracardiac
echocardiography of endomyocardial injections, direct
leakage of microbubble-containing injectate was demon-
strated (data not shown).
DISCUSSION
Injectate Leakage
The intramuscular route has long been used for sys-
temic drug delivery [14,15]. Our data suggest that car-
diac intramuscular delivery also leads to significant sys-
temic exposure of injectate in that a substantial
proportion of injected material immediately exits the
myocardium. During direct epicardial injection, we ob-
serve obvious egress of material associated with cardiac
systole after withdrawal of the injection needle. More-
over, using continuous intracardiac echocardiography,
direct leakage of microbubble-containing injectate is eas-
ily demonstrated.
In addition to direct leakage, injectate may exit the
myocardium via cardiac venous or lymphatic channels.
The myocardium, like all muscle tissue, is highly vascu-
lar, with extensive vascular drainage [16]. Reporter gene
detection in coronary sinus tissue, above regional back-
ground, suggests a component of venous return of ad-
ministered viral vector [17,18]. Therefore, once escaping
cardiac tissue, nontarget organs may be exposed to the
injected material [9].
Retention Is Greater After Endomyocardial Than
After Epicardial Injection
We found equivalent or superior retention of material
injected into the myocardium via endocardial catheter
compared with epicardial surgical needle. Transmural
inhomogeneity of hemodynamic and physical forces may
underlie this observation [19,20]. For example, subendo-
cardial tissue is predisposed to ischemia and infarction
earlier after coronary occlusion than is subepicardial
tissue [21,22]. Conceivably similar forces act to extrude
subepicardial more than subendocardial injectate. Simi-
larly, it is possible that endocardial injection may afford
deeper delivery of injectate.
Endomyocardial injection is clinically more attractive
than direct surgical injection. Many patients who are
candidates for protein- or gene-based direct myocardial
therapy have undergone or will require cardiac surgery
[23]. Transepicardial access generally entails higher pa-
tient morbidity and, for example, might endanger viable
bypass grafts. Moreover, repeat direct myocardial drug
administration is potentially more feasible via a trans-
catheter approach.
Methods That Might Improve Retention
We found that smaller-volume injection of more con-
centrated suspensions or solutions leads to improved
Fig. 3. Injection volume influences viral transfection. There
was a trend towards improved viral transfection associated
with the smaller-volume endomyocardial injections compared
with the larger-volume endomyocardial injections.
Fig. 4. Coronary sinus -galactosidase activity. There was an
insignificant trend towards greater viral transfection associated
with the larger-volume injections compared with the smaller-
volume injections. †: p  0.05 compared with 100 l volume
injection; ‡: p  0.08 compared with 100 l volume injection.
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myocardial retention, conceivably by reducing the phys-
ical or hemodynamic tissue displacement by injectate.
Other methods that might improve retention include al-
terations in vehicle viscosity, osmolarity, or charge.
Other investigators have even explored local alterations
in tissue permeability, for example, by insonation [24] or
electroporation [25,26].
Fluoroscopic Guidance of Endomyocardial
Injections
We were able to access all myocardial segments using
monoplane fluoroscopic guidance, and there was no ev-
idence of sustained arrhythmia, myocardial perforation,
or damage to the mitral valve apparatus. Similar safety
and procedural success has been demonstrated using
more elaborate geographic localization technologies,
such as three-dimensional electromechanical mapping
[7–9]. In comparison, a fluoroscopic-guided injection
catheter is simpler, less expensive, and potentially faster.
Advantages and Goal of Direct Myocardial
Delivery
Direct myocardial delivery of therapeutic agents for
the treatment of coronary artery and myocardial disease
is potentially advantageous. Compared with other forms
of delivery, direct myocardial delivery is attractive be-
cause specific myocardial regions can be targeted, and
higher local concentrations of agent can be achieved [9].
In one biodistribution study, less than 1% of radiolabeled
basic fibroblast growth factor activity was recovered in
the myocardium shortly after intracoronary or intrave-
nous administration [27]. Conceivably, a smaller total
dose of agent can be administered intramuscularly,
thereby lowering systemic exposure and potential non-
target organ toxicity.
Study Limitations
The microsphere control counts have a high variabil-
ity, possibly due to settling of the dense microspheres.
While frequent agitation of the injectate was attempted,
some settling of the microspheres within the injection
system was possible.
These studies were performed in nonischemic myocar-
dium. Direct myocardial injection tolerability and injec-
tate retention in ischemic or nonviable myocardium may
be different than the retention in normal cardiac tissue. In
addition, the retention was evaluated in a single postin-
jection time point and retention over time was not eval-
uated. Finally, adenoviral transfection may be higher at
higher viral particle concentrations; therefore, our finding
of greater viral transfection at low injectate volumes
conceivably may represent this inoculum effect in addi-
tion to more effective retention of a lower-volume injec-
tate, as suggested in the microsphere studies.
Direct myocardial injection was well tolerated. A sig-
nificant fraction of injectate is not retained locally. We
found that injectate retention after catheter-based endo-
myocardial injection is equivalent or superior to open
chest epicardial injection. Finally, injectate retention may
be greater at lower injectate volumes. Catheter-based
endomyocardial injection is a promising strategy for lo-
cal drug delivery.
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